Stoke Therapeutics, Inc. (STOK) Cash Flow Statement
Stoke Therapeutics, Inc. (STOK) generated -$178.0M of operating cash flow over the twelve months to 2026-06-30, spent $2.7M on capital expenditure and had free cash flow of -$180.7M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
STOKStoke Therapeutics, Inc.Follow STOK — free
—
Price chart with a free account
- Market cap
- 1.6B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 2 Nov, in 9 days
| Line | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|
| Operating cash flow | -31.9 | -81.1 | -86.9 | 45.6 | -178.0 | |
| Capital expenditure | 4.0 | 1.6 | 0.2 | 0.7 | -2.7 | |
| Free cash flow | -35.8 | -82.7 | -87.1 | 44.9 | -180.7 | |
| Stock-based compensation | 22.9 | 25.3 | 27.5 | 32.2 | — |
USD millions · SEC XBRL
Stoke Therapeutics, Inc. — questions
- What is Stoke Therapeutics, Inc.'s operating cash flow?
- -$178.0M over the twelve months to 2026-06-30.
- How much does Stoke Therapeutics, Inc. spend on capital expenditure?
- $2.7M over the twelve months to 2026-06-30.
- What is Stoke Therapeutics, Inc.'s free cash flow?
- -$180.7M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Stoke Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.